Travere Therapeutics, Inc. (TVTX) News

Travere Therapeutics, Inc. (TVTX): $20.08

0.54 (+2.76%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add TVTX to Watchlist
Sign Up

Industry: Biotech


Ranked

of 381

in industry

Filter TVTX News Items

TVTX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

TVTX News Highlights

  • For TVTX, its 30 day story count is now at 4.
  • Over the past 13 days, the trend for TVTX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • The most mentioned tickers in articles about TVTX are NOV, RARE and CMRX.

Latest TVTX News From Around the Web

Below are the latest news stories about TRAVERE THERAPEUTICS INC that investors may wish to consider to help them evaluate TVTX as an investment opportunity.

Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN DIEGO, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that on November 10, 2022, the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 173,000 shares of its common stock to 12 new employees, consisting of inducement stock options to purchase an aggregate of 90,000 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 83,000 shares of its common stock

Yahoo | November 16, 2022

Travere Therapeutics, the IgA Nephropathy Foundation, and NephCure Kidney International Partner to Launch RKD & Me, a Campaign to Raise Awareness of Rare Kidney Disease

Developed in collaboration with the rare kidney disease community, RKD & Me aims to amplify the experiences of people living with rare kidney disease. SAN DIEGO, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., the IgA Nephropathy Foundation, and NephCure Kidney International today announced the launch of RKD & Me, a new public awareness campaign that spotlights the real stories of people living with rare kidney disease to amplify their unique lived experiences, educate the public,

Yahoo | November 15, 2022

Travere Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will participate in the following upcoming conferences: Jefferies 2022 London Healthcare ConferenceWednesday, November 16, 2022, at 4:25 p.m. GMT (11:25 a.m. ET) 5th Annual Evercore ISI HealthCONx ConferenceTuesday, November 29, 2022, at 1:25 p.m. ET Piper Sandler Healthcare ConferenceThursday, December 1, 2022, at 10:30 a.m. ET BofA Securities 2022 Biotech SMID Cap Conf

Yahoo | November 9, 2022

Analysts Offer Insights on Healthcare Companies: Chimerix (CMRX), Travere Therapeutics (TVTX) and Karuna Therapeutics (KRTX)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Chimerix (CMRX – Research Report), Travere Therapeutics (TVTX – Research Report) and Karuna Therapeutics (KRTX – Research Report) with bullish sentiments. Chimerix (CMRX) JonesTrading analyst Soumit Roy reiterated a Buy rating on Chimerix today and set a price target of $5.00. The company's shares closed last Thursday at $1.86, close to its 52-week low of $1.27. According to TipRanks.

Brian Anderson on TipRanks | November 3, 2022

Travere Therapeutics Reports Third Quarter 2022 Financial Results

EMA accepted for review the Conditional Marketing Authorization application for sparsentan for IgAN in Europe; review decision expected in second half of 2023 New PDUFA target action date for sparsentan in IgAN set for February 17, 2023 Net product sales of $50.8 million for the third quarter of 2022 SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its third quarter 2022 financial results and provided a corporate update. European Medicines Age

Yahoo | October 27, 2022

Travere Therapeutics Announces Presentations and Posters at American Society of Nephrology Kidney Week 2022

Data support the Company’s lead investigational product candidate sparsentanSAN DIEGO, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present data from its sparsentan programs, including long-term clinical data from the ongoing Phase 2 DUET Study in focal segmental glomerulosclerosis (FSGS), as well as non-clinical data exploring the potential for sparsentan to protect kidney function at the American Society

Yahoo | October 26, 2022

SVB Securities Keeps Their Buy Rating on Travere Therapeutics (TVTX)

SVB Securities analyst Joseph Schwartz maintained a Buy rating on Travere Therapeutics (TVTX - Research Report) today and set a price target of $38.00. The company's shares opened today at $22.55.According to TipRanks, Schwartz is an analyst with an average return of -16.6% and a 31.25% success rate. Schwartz covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Travere Therapeutics, and BioMarin Pharmaceutical.The word on The Street in general, suggests a Strong Buy analyst consensus rating for Travere Therapeutics with a $38.40 average price target, representing a 70.29% upside. In a report released on October 14, H.C.

Howard Kim on TipRanks | October 20, 2022

Travere Therapeutics to Report Third Quarter 2022 Financial Results

SAN DIEGO, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report third quarter 2022 financial results on Thursday, October 27, 2022, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. Conference Call Information Date:Thursday, October 27, 2022Time:4:30 p.m. ETDial-in numbers:+1 (888) 394-8218 (U.S.) or +1 (323

Yahoo | October 20, 2022

Travere Therapeutics Provides Regulatory Update on its Sparsentan Program for IgA Nephropathy

Conference call and webcast to be held at 4:30p.m. ET SAN DIEGO, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that following late-cycle review interactions with the U.S. Food and Drug Administration (FDA), the Company expects the previously assigned Prescription Drug User Fee Act (PDUFA) target action date of November 17, 2022 for its New Drug Application (NDA) under Subpart H for accelerated approval of sparsentan for the treatment of IgA nephropat

Yahoo | October 13, 2022

Insider Buying 2022: 15 Stocks to Bet On Despite the Bear Market

Following insider buying is a savvy way for retail investors to profit even when a bear market is raging on Wall Street.

Thomas Yeung on InvestorPlace | October 5, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6284 seconds.